MedTrace Logo

An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD

NCT02228655 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-02-02

No results posted yet for this study

Summary

FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.

Conditions

  • Anemia in Chronic Kidney Disease

Interventions

DRUG

FMX-8

Sponsors & Collaborators

  • FerruMax Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Stewart Lecker, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-04-30
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228655 on ClinicalTrials.gov